Understanding DNA Damage Response and DNA Repair Pathways: Applications to More Targeted Cancer Therapeutics

Seminars in Oncology

Volumn 36, Issue SUPPL. 1, 2009, Pages

  Kinsella, Timothy J ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 5 AZA 2' DEOXYCYTIDINE; 6 O BENZYLGUANINE; 7 HYDROXYSTAUROSPORINE; AG 014699; AZD 2281; AZD 7762; BEVACIZUMAB; BSI 201; CARBOPLATIN; CEP 8983; CISPLATIN; DACARBAZINE; ETOPOSIDE; FLUOROPYRIMIDINE; GEMCITABINE; INO 1001; IRINOTECAN; KU 59436; LOMEGUATRIB; METHOXYAMINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MITOMYCIN C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PF 00477736; TEMOZOLOMIDE; TOPOTECAN; TRC 102; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 844;

ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SUSCEPTIBILITY; CANCER THERAPY; CELL CYCLE REGULATION; CELL DEATH; CELL SURVIVAL; COLORECTAL CARCINOMA; DNA DAMAGE; DNA DAMAGE RESPONSE; DNA REPAIR; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG TARGETING; HUMAN; IONIZING RADIATION; MELANOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE DRUG DOSE; SOLID TUMOR; UTERUS CANCER;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DNA DAMAGE; DNA REPAIR; DRUG DESIGN; HUMANS; NEOPLASMS;

EID: 64849095109     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2009.02.004     Document Type: Article

References (49)

1. Kastan M.B. DNA damage responses: mechanisms and roles in human disease: 2007 G.H.A. Clowes Memorial Award Lecture. Mol Cancer Res 6 (2008) 517-524
2. Harper J.W., and Elledge S.J. The DNA damage response: ten years after. Mol Cell 28 (2007) 739-745
3. Helleday T., Petermann E., Lundin C., Hodgson B., and Sharma R.A. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8 (2008) 193-204
4. Kinsella T.J. Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers. Clin Cancer Res (2009)
5. Cline S.D., and Hanawalt P.C. Who's on first in the cellular response to DNA damage?. Nat Rev Mol Cell Biol 4 (2003) 361-372
6. Bradbury J.M., and Jackson S.P. The complex matter of DNA double-strand break detection. Biochem Soc Trans 31 (2003) 40-44
7. Workman C.T., Mak H.C., McCuine S., Tagne J.B., Agarwal M., Ozier O., et al. A systems approach to mapping DNA damage response pathways. Science 312 (2006) 1054-1059
8. Matsuoka S., Ballif B.A., Smogorzewska A., McDonald III E.R., Hurov K.E., Luo J., et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316 (2007) 1160-1166
9. Loeb L.A., Loeb K.R., and Anderson J.P. Multiple mutations and cancer. Proc Natl Acad Sci U S A 100 (2003) 776-781
10. Chompret A. The Li-Fraumeni syndrome. Biochimie 84 (2002) 75-82
11. Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 7 (2006) 335-346
12. Domchek S.M., and Weber B.L. Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene 25 (2006) 5825-5831
13. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat Med 10 (2004) 789-799
14. Taniguchi T., and D'Andrea A.D. Molecular pathogenesis of Fanconi anemia: recent progress. Blood 107 (2006) 4223-4233
15. Cleaver J.E. Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat Rev Cancer 5 (2005) 564-573
16. Valerie K., and Povirk L.F. Regulation and mechanisms of mammalian double-strand break repair. Oncogene 22 (2003) 5792-5812
17. David S.S., O'Shea V.L., and Kundu S. Base-excision repair of oxidative DNA damage. Nature 447 (2007) 941-950
18. Chan K.K., Zhang Q.M., and Dianov G.L. Base excision repair fidelity in normal and cancer cells. Mutagenesis 21 (2006) 173-178
19. Jagtap P., and Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4 (2005) 421-440
20. Sedgwick B. Repairing DNA-methylation damage. Nat Rev Mol Cell Biol 5 (2004) 148-157
21. 6-alkylguanine DNA alkyltransferase inhibitors. Expert Opin Investig Drugs 16 (2007) 1573-1584
22. Kesseler K.J., Kaufmann W.K., Reardon J.T., Elston T.C., and Sancar A. A mathematical model for human nucleotide excision repair: damage recognition by random order assembly and kinetic proofreading. J Theor Biol 249 (2007) 361-375
23. Iyer R.R., Pluciennik A., Burdett V., and Modrich P.L. DNA mismatch repair: functions and mechanisms. Chem Rev 106 (2006) 302-323
24. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 21 (2003) 1174-1179
25. O'Brien V., and Brown R. Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis 27 (2006) 682-692
26. Zeng X., and Kinsella T.J. A novel role for DNA mismatch repair and the autophagic processing of chemotherapy drugs in human tumor cells. Autophagy 3 (2007) 368-370
27. Hong Z., Jiang J., Hashiguchi K., Hoshi M., Lan L., and Yasui A. Recruitment of mismatch repair proteins to the site of DNA damage in human cells. J Cell Sci 121 (2008) 3146-3154
28. Karran P. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis 22 (2001) 1931-1937
29. National Cancer Institute. Integrative Cancer Biology Program. http://icbp.nci.nih.gov Accessed October 22, 2008
30. Reinhardt H.C., Aslanian A.S., Lees J.A., and Yaffe M.B. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11 (2007) 175-189
31. Marchetti S., and Schellens J.H. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br J Cancer 97 (2007) 577-581
32. Doroshow J.H., and Parchment R.E. Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient. Clin Cancer Res 14 (2008) 3658-3663
33. Murgo A.J., Kummar S., Rubinstein L., Gutierrez M., Collins J., Kinders R., et al. Designing phase 0 cancer clinical trials. Clin Cancer Res 14 (2008) 3675-3682
34. Calvert A.H., and Plummer R. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials. Clin Cancer Res 14 (2008) 3664-3669
35. Curtin N.J. PARP inhibitors for cancer therapy. Expert Rev Mol Med 7 (2005) 1-20
36. Plummer E.R. Inhibition of poly(ADP-ribose) polymerase in cancer. Curr Opin Pharmacol 6 (2006) 364-368
37. Ratnam K., and Low J.A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 13 (2007) 1383-1388
38. Miknyoczki S., Chang H., Grobelny J., Pritchard S., Worrell C., McGann N., et al. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol Cancer Ther 6 (2007) 2290-2302
39. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26 (2008) 3785-3790
40. Plummer R., Lorigan P., Evans J., Steven N., Middleton M., Wilson R., et al. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J Clin Oncol 24 (2006) 456s (abstr 8013)
41. Kaelin Jr. W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5 (2005) 689-698
42. Hartwell L.H., Szankasi P., Roberts C.J., Murray A.W., and Friend S.H. Integrating genetic approaches into the discovery of anticancer drugs. Science 278 (1997) 1064-1068
43. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
44. 6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26 (2008) 4189-4199
45. Liu L., and Gerson S.L. Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr Opin Investig Drugs 5 (2004) 623-627
46. Plumb J.A., Strathdee G., Sludden J., Kaye S.B., and Brown R. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60 (2000) 6039-6044
47. Berry S.E., and Kinsella T.J. Targeting DNA mismatch repair for radiosensitization. Semin Radiat Oncol 11 (2001) 300-315
48. Seo Y., Yan T., Schupp J.E., Colussi V., Taylor K.L., and Kinsella T.J. Differential radiosensitization in DNA mismatch repair-proficient and -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2'-deoxyribose. Clin Cancer Res 10 (2004) 7520-7528
49. Ashwell S., and Zabludoff S. DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 14 (2008) 4032-4037